Evidence map›Paper›PMID 39402022›Full record

ArticleBlood cancer journal2024

Patient preferences for intervention in the setting of precursor multiple myeloma.

Catherine R Marinac, Katelyn Downey, Jacqueline Perry, Brittany Fisher-Longden, Timothy R Rebbeck, Urvi A Shah, Elizabeth K O'Donnell, Irene M Ghobrial, Omar Nadeem, Brian L Egleston

Erratum issuedAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Catherine R MarinacDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US. catheriner_marinac@dfci.harvard.edu.ORCID 0000-0002-9128-3012
Katelyn DowneyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US.ORCID 0000-0002-8782-4971
Jacqueline PerryDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US.
Brittany Fisher-LongdenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US.
Timothy R RebbeckDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US.ORCID 0000-0002-4799-1900
Urvi A ShahDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, US.ORCID 0000-0001-8419-1091
Elizabeth K O'DonnellDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US.
Irene M GhobrialDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US.ORCID 0000-0001-7361-3092
Omar NadeemDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US.
Brian L EglestonFox Chase Cancer Center, Philadelphia, PA, US.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Repurposing Metformin for the Prevention of Disease Progression in Precursor Multiple MyelomaK22CA251648 · NCI · DANA-FARBER CANCER INST · PI MARINAC, CATHERINE · 2020 to 2022
$577k
Prolonged Nightly Fasting as a Behavioral Intervention for Obesity Reduction and the Prevention of Progression in Precursor Multiple MyelomaR21CA256644 · NCI · DANA-FARBER CANCER INST · PI MARINAC, CATHERINE · 2022 to 2023
$453k
EIF | Stand Up To Cancer (SU2C) SU2C-AACR-DT-28-18NCI NIH HHS K22 CA251648NCI NIH HHS P30 CA008748NCI NIH HHS R21 CA256644
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Multiple MyelomaPatient PreferenceAdultAgedFemaleHumansMaleMiddle Aged

Identifiers

PMID39402022
PMCPMC11473799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.